News
We send the latest information from SMC Laboratories.
Enhance Research with Our Updated Model Lineup
We are introducing new disease models to our portfolio of preclinical mouse models. Our extensive lineup offer…
Results of Resmetirom fibrosis targeting study using STAM™ model
Recently, we have obtained the results of a study of resmetirom for the treatment of fibrosis using STAMTM-HCC…
MOA demonstration #4 【Gut-Liver Axis】｜Evaluation of the efficacy of a compound in the treatment of MASH via the Gut-Liver Axis using STAM™ mice
Today, we introduce the pre-clinical studies in MASH drug development targeting Gut-Liver axis. In MASH…
Case study: Study published in Biomolecules on the effects of MSC-sEV in skin fibrosis of BLM-SSc model.
We introduce a case study of drug efficacy evaluation of Mesenchymal stem/stromal cell-derived small extracell…
Preclinical COPD study with positive controls, Roflumilast
Today, we share an update regarding new preclinical service. It is now possible to use a positive control (Rof…
The STAM™ mouse: a clinically relevant, spontaneous HCC model
We would like to introduce a study published by our client using our STAM™ mouse (Dow, et al. Proc Natl Acad S…
Introducing our skin disease model: Imiquimod (IMQ)-induced psoriasis model
Today, from our lineup of pathological models, we would like to introduce the imiquimod (IMQ)-induced dermatit…
MOA demonstration #3 【GLP-1】｜Evaluation of GLP-1 targeted MASH treatment efficacy using STAM™ mice
Today, we introduce the pre-clinical studies in MASH drug development targeting GLP-1. Speaking of GLP-…
Custom Model Service and its case study “CAIA-Rheumatoid Arthritis Model”
In recent years, we have received many requests about our services, starting from the establishment of patholo…
MOA demonstration #2【diponectin】｜A drug efficacy evaluation study using STAM™ mice “Inhibition of MASH and fibrosis progression by adiponectin-derived peptide”.
We introduce the pre-clinical studies in MASH drug development using Adiponectin, adipoR1 , adipoR2, etc. as M…